Geistlich Signs Agreement with Suzhou Industrial Park to Establish First Oral Biomaterial Intelligent Manufacturing Base Outside Europe

DentalGoodNews｜On April 16, 2026, Geistlich Group officially signed an agreement with the Suzhou Industrial Park. The group will invest in the park to build its first self-owned brand oral biomaterial intelligent manufacturing base outside Switzerland. It will introduce pillar products such as bone filling materials and absorbable biological membranes for localized production.

According to Geistlich Group, the signing ceremony was held in Suzhou. Jürg Roth, Chief Financial Officer of Geistlich Group, and Bian Yuchun, Deputy Director of the Investment Promotion Bureau of Suzhou Industrial Park, signed the agreement. Wang Wei, Acting Mayor of Suzhou; Shen Mi, Member of the Standing Committee of the Suzhou Municipal Party Committee and Secretary of the Party Working Committee of Suzhou Industrial Park; Fabian Peter, Deputy Governor of the Canton of Lucerne, Switzerland and Head of the Department of Economic Affairs, Infrastructure and Environment; and Liao Ning, General Manager of Geistlich China attended the signing ceremony.

Founded in 1851 and headquartered in the Canton of Lucerne, Switzerland, Geistlich Group's subsidiary Geistlich Pharma AG focuses on the production of biomaterials for bone, cartilage, and tissue regeneration. Its Bio-Oss bone substitute material and Bio-Gide absorbable collagen barrier membrane are commonly used materials in the fields of dental implantation and periodontal regeneration. Currently, the group has 15 subsidiaries worldwide, and its products cover more than 110 countries and regions.

According to the agreement, Geistlich Group will settle in the BioBAY biomedical industrial park in the core area of Suzhou Industrial Park and include some products in its localization scope. This marks the first time in the group's 175-year history that it has established a self-owned oral biomaterial brand manufacturing base outside Switzerland.

Image source: BioBAY official website, the biomedical industrial park in the core area of Suzhou Industrial Park.

According to public information, the biomedical and healthcare industry in Suzhou Industrial Park achieved an output value of 175.5 billion yuan in 2025 and has gathered over 2,000 related enterprises, making it a key industry in the park. The park stated that it had provided assistance in product registration, review and approval, and policy interpretation during the project's preliminary stage. In March 2026, Daniele Jüngling, Vice President of Supply Chain and Production at Geistlich, led a delegation to visit Suzhou Industrial Park, laying the foundation for this official signing.

Regarding the cooperation arrangements in China, Geistlich stated that this investment in Suzhou does not affect the group's strategic partnership with Shandong Junxiu Biotechnology Co., Ltd. Both parties will continue to provide oral regenerative biomaterial products to the Chinese market.

As of press time, Geistlich Group has not disclosed the specific investment amount or the timeline for the construction of this intelligent manufacturing base project.